Molecular design, synthesis and biological research of novel pyridyl acridones as potent DNA-binding and apoptosis-inducing agents
- 1 March 2015
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 93, 214-226
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology of China (2012AA020305, 2013AA092902)
- Chinese National Natural Science Foundation (21272134, 21372141)
- Shenzhen municipal government SZSITIC (JCYJ20120831165730905, JCYJ20130402164027386)
This publication has 44 references indexed in Scilit:
- A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer ProdrugsJournal of Medicinal Chemistry, 2014
- New Pyrrole Derivatives with Potent Tubulin Polymerization Inhibiting Activity As Anticancer Agents Including Hedgehog-Dependent CancerJournal of Medicinal Chemistry, 2014
- Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer2014
- Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin as Potent Antitumor AgentsJournal of Medicinal Chemistry, 2014
- 1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer CellsJournal of Medicinal Chemistry, 2014
- Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohortGastric Cancer, 2013
- Niche for Acridine Derivatives in Anticancer TherapyMini-Reviews in Medicinal Chemistry, 2013
- Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT TrialClinical Cancer Research, 2013
- Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck CancerThe Oncologist, 2013
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnnals of Oncology, 2012